The number and quality of interactions at the European Academy of Neurology 2024 congress in Helsinki indicate the potential ground-breaking role that @cartcelltherapy could play in B cell-driven neurological #autoimmunedisease. A big Thank You to all who stopped by and spent time at our Kyverna Therapeutics booth. #KYV101
Kyverna Therapeutics’ Post
More Relevant Posts
-
Navigating migraine medications can be difficult, and we're here to help provide some guidance during our Instagram Live on March 19th at 3 PM with Dr. Yablon, MD from the virtual neurology clinic Neura Health. Are you wondering about the ideal trial duration, what defines success or failure, or how to transition off a medication? Bring your questions and your notebook as we discuss trialing some of the popular new medications like CGRP monoclonal antibodies, onabotulinumtoxinA, neuromodulation devices, and more! Be sure to check us out on IG at https://lnkd.in/e2fQqKJC!
To view or add a comment, sign in
-
-
📄 July #eanResearchHighlights present key findings in neurology: ➡️The N-MOmentum trial's open-label period shows sustained benefits of inebilizumab, a B-cell depleting anti-CD19 antibody, for NMOSD, including lower attack rates and fewer hospitalisations. ➡️ A phase 2 trial reveals brigatinib, a tyrosine kinase inhibitor, as a potential treatment for NF2-related schwannomatosis, with reduced tumour growth and improved symptoms. 🔗 Read more here: https://ow.ly/b5hE50SIsx9
To view or add a comment, sign in
-
-
During our time at #KidneyWk, we sat down with Richard Lafayette, MD, of Stanford Health Care, and discussed the latest data in IgA nephropathy, including data from the ORIGIN-3 trial of atacicept (Vera Therapeutics, Inc.). Check out the preview and learn more: https://lnkd.in/d8eauakC #Nephrology
To view or add a comment, sign in
-
𝐂𝐑𝐈𝐒𝐏𝐑-𝐌𝐨𝐝𝐢𝐟𝐢𝐞𝐝 𝐌𝐞𝐬𝐞𝐧𝐜𝐡𝐲𝐦𝐚𝐥 𝐒𝐭𝐫𝐨𝐦𝐚𝐥 𝐂𝐞𝐥𝐥𝐬 𝐒𝐡𝐨𝐰 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜 𝐏𝐨𝐭𝐞𝐧𝐭𝐢𝐚𝐥 𝐢𝐧 𝐎𝐬𝐭𝐞𝐨𝐚𝐫𝐭𝐡𝐫𝐢𝐭𝐢𝐬 In an article published in Molecular Therapy, researchers at Rush University Medical Center in Chicago report that simultaneous Sox9 activation and RelA inhibition using a catalytically-dead Cas9 resulted in engineered mesenchymal stromal cells with enhanced cartilage-forming potential and downregulated inflammatory responses. Read more 👇🏻 https://lnkd.in/emZxa_HE #crisprmedicinenews #crisprmedicine #crispr #geneediting #osteoarthritis
To view or add a comment, sign in
-
The golden age of #biotechnology continues to catalyze the engineering of novel advanced #research tools and the concomitant development of high-value research and clinical applications. How is the development in 2024 and beyond? #Proteomics is experiencing growth and investment in scaling precision medicine applications, particularly in oncology. The precision medicine tool kit is expanding beyond oncology into neurology, autoimmune diseases and inflammatory diseases, shaping the industry's future. https://lnkd.in/gyNeN3s5 #lifescience #clinicaldiagnostic #biopharma #nextemergingtrends #precisionmedicine
To view or add a comment, sign in
-
-
Learn the key considerations for utilizing #RANO 2.0 criteria when assessing #Glioblastoma treatments in #ClinicalTrials. Read the blog by Calyx's Elif Sikoglu https://lnkd.in/gp8G-rv6 #MedicalImaging #NeuroOncology #ChooseCalyx
Implementing RANO 2.0 in Glioblastoma Clinical Trials | Calyx
calyx.dsmn8.com
To view or add a comment, sign in
-
A recent RCT published in #Med, IPE-PREVENTION CardioLink-14, provides the first translational evidence that icosapent ethyl (IPE) can modulate vascular regenerative cell content and increase pro-vascular progenitor cells in patients with hypertriglyceridemia. These findings provide a potential mechanism for the observed cardiovascular benefits of IPE therapy in the previous REDUCE-IT trial. https://lnkd.in/eCVkwcPd #cardiovascularhealth #icosapentethyl #vascularregeneration #hypertriglyceridemia #clinicaltrial
Icosapent ethyl modulates circulating vascular regenerative cell content: The IPE-PREVENTION CardioLink-14 trial
cell.com
To view or add a comment, sign in
-
🎉🌟 Hats off to Ben Cadieux, Executive Director at Arvinas (Former), currently in Cygnus Therapeutics, for his outstanding role as Chairperson for Day 1 at the 20th BioPharma Clinical Trials Nexus Event! 📣His adept management ensured the smooth flow of discussions & significantly contributed to the success of this event. Ben also shared insightful perspectives on "Precision Medicine in Neurology: A Medical Affairs Perspective" 🌟Thank you Ben for guiding us through a world of knowledge and innovation. Don't miss out on his exceptional insights! #Clinicaltrials #20thBioPharma #Procurementdirect #Medicalaffairs #Neurology #ClinicalOperations #NexusConference #Medicine #
To view or add a comment, sign in
-
-
Why do some patients respond better to immunotherapy than others? A team led by scientists here at BWH has published a paper revealing new details about the tumor characteristics that facilitate a strong clinical response to these drugs. “What we’ve shown here is that patients are not necessarily doomed to not respond if they have low levels of TCF1. Additionally, for those patients who do have low levels, there are ways that we can boost their response,” says Ana C. Anderson, PhD, from the department of neurology. To learn more about patients' response to immunotherapy and more on the study, check out the article below: https://lnkd.in/eBXY_639
To view or add a comment, sign in
-
-
📊 MGMA 2024 data reveals intriguing trends in compensation and production changes across medical specialties! 🚑 Emergency medicine: Watch out! Compensation down, but production up! 📈 Internal medicine, oncology, hematology, and pathology rejoice! Compensation and production on the rise! 🤔 Neurology shows a compensation increase, but production takes a hit. What's up with that? 🤔 Need help navigating these trends? Customization is key! Every situation is unique, and we've got your back. #MGMA2024 #HealthcareTrends #CompensationProduction #MedicalSpecialties #DataInsights
To view or add a comment, sign in